This comparison adjusts for several clinical factors including age, grade, tumor size, estrogen receptor (ER) status, and Human Epidermal Growth Factor Receptor 2 (HER2) status to ensure that the BRCAness characteristic profile reflects BRCA1/2 mutation status rather than differences in the distribution of these clinical variables across patients. This evidence concerns the gene ERBB2 and neoplasm.